Novo Nordisk announced this morning that it is ending its partnership with Hims & Hers, which allowed the telehealth provider to sell Novo's blockbuster weight-loss drug, Wegovy.

CagriSema shows mild-to-moderate side effects in trials Researcher sees benefit to additional weight-loss options Novo Nordisk plans regulatory filing for CagriSema in early 2026 June 22 (Reuters ...

COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish ...

Novo Nordisk NVO ended its collaboration agreement with telehealth company Hims & Hers Health HIMS to offer its blockbuster obesity drug Wegovy (semaglutide) at a discounted price to cash-paying ...

A simple oversight could end up costing Danish pharma giant Novo Nordisk A/S (NYSE: NVO) billions in potential losses on its blockbuster weight-loss and diabetes drug, Ozempic.

Neither of these developments is positive for Novo Nordisk. However, investors didn't react by panic-selling the stock; instead, it suffered only a minor sell-off.

Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a condition called peripheral artery disease.

Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish pharmaceutical company. Zepbound, a direct competitor to Novo Nordisk's pioneering ...

Novo Nordisk's abrupt exit from its Hims partnership on 23 June 2025 highlights a critical divide in the booming weight-loss drug market, balancing affordability with safety.

Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing ...